Cowen Starts Day One Biopharmaceuticals (DAWN) at Outperform
Tweet Send to a Friend
Cowen analyst Marc Frahm initiates coverage on Day One Biopharmaceuticals (NASDAQ: DAWN) with a Outperform rating.The analyst comments "Day One's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
